MicroPort CardioFlow Medtech (HKSE:02160) ROCE % : -22.43% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is MicroPort CardioFlow Medtech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. MicroPort CardioFlow Medtech's annualized ROCE % for the quarter that ended in Dec. 2023 was -22.43%.

MicroPort CardioFlow Medtech ROCE % Historical Data

The historical data trend for MicroPort CardioFlow Medtech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort CardioFlow Medtech ROCE % Chart

MicroPort CardioFlow Medtech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-58.57

-11.29

-14.09

-17.46

MicroPort CardioFlow Medtech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial					-6.85	-7.40	-21.63	-12.39	-22.43

MicroPort CardioFlow Medtech ROCE % Calculation

MicroPort CardioFlow Medtech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-502.774	/	( ( (3351.552 - 197.914)	+	(2818.786 - 211.737) )	/ 2 )
	=	-502.774	/	( (3153.638	+	2607.049)	/ 2 )
	=	-502.774	/	2880.3435
	=	-17.46 %

MicroPort CardioFlow Medtech's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-625.952	/	( ( (3172.516 - 198.199)	+	(2818.786 - 211.737) )	/ 2 )
	=	-625.952	/	( ( 2974.317	+	2607.049 )	/ 2 )
	=	-625.952	/	2790.683
	=	-22.43 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

MicroPort CardioFlow Medtech (HKSE:02160) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

MicroPort CardioFlow Medtech ROCE % Related Terms

Thank you for viewing the detailed overview of MicroPort CardioFlow Medtech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

MicroPort CardioFlow Medtech (HKSE:02160) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort CardioFlow Medtech Corp (HKSE:02160) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

72X:Germany

Address

No. 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, CHN, 201203

Website

https://www.cardioflowmedtech.com

MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.

MicroPort CardioFlow Medtech (HKSE:02160) Headlines

No Headlines